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The genetic susceptibility to IgA 
nephropathy: A novel functional 
candidate gene for incomplete O-
glycosylation of IgA1
I Narita1, Y Kaneko1, D Kondo1, S Goto1, M Sakatsume1 and F Gejyo1
Incompleteness of O-glycosylation in the IgA1 hinge has been 
implicated as a central mechanism in the development of IgA 
nephropathy. Although underglycosylation was reported to be an 
acquired abnormality, genes for enzymes of O-glycosylation, such as 
C1GALT1, may be responsible for susceptibility to IgA nephropathy.
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IgA nephropathy (IgAN), the most com-
mon form of primary glomerulonephritis 
worldwide, is defi ned as the predominant 
IgA1 deposits in the glomerular mesan-
gium. Although the mechanism of the 
deposition remains uncertain, genetic 
factors are considered to underlie the 
development of IgAN. Several candidate 
gene loci and genes have been reported, 
including IGAN1 at 6q22–23;1 however, 
the pathogenic meaning of these in the 
development of IgAN remains elusive. 
While linkage analysis is arguably the 
most powerful method for identifying a 
locus involving rare, high-risk alleles in 
mendelian diseases, genetic association 
analysis is generally considered another 
eff ective method for identifying genetic 
variants related to common and complex 
diseases, as is the case in IgAN.
During the past decade, several lines of 
evidence have been reported indicating 
that incompleteness of O-glycosylation in 
the IgA1 hinge region may be a plausible 
cause of the IgA1 deposition. O-Glycans 
are found in many glycoproteins, par-
ticularly in secretory glycoproteins. Th e 
common core 1 O-glycan structure Galβ-
1-3GalNAc-R is a precursor for many 
extended mucin-type O-glycan struc-
tures on animal-cell surfaces and secreted 
glycoproteins including IgA1. Th e hinge 
region of human IgA1 possesses multiple 
O-glycans, of which synthesis is initiated 
by the addition of GalNAc to serine or 
threonine residues through the activity 
of UDP-N-acetyl-α-d-galactosamine:
polypeptide N-acetylgalactosaminyltrans-
ferases (pp-GalNAc-Ts), followed by core 
1 synthase 1, also called glycoprotein-N-
acetylgalactosamine 3-β-galactosyltrans-
ferase 1, core 1 β3-Gal-T, or T-synthase 
(C1GALT1) (Figure 1).2,3 Aberrantly glyc-
osylated IgA1 molecules readily self-aggre-
gate and tend to form antigen–antibody 
immune complexes with IgG antibodies 
against epitopes in the IgA1 hinge region, 
favoring the generation of macromolecu-
lar aggregates of polymeric IgA1 and IgA 
immune complexes.4,5 Moreover, IgA1 
defi cient in terminal sialic acid and galac-
tose unit shows increased in vitro adhe-
sion to extracellular matrix components, 
such as fi bronectin, type IV collagen, and 
laminin.5 In addition, circulating immune 
complexes containing aberrantly glyco-
sylated IgA1 aff ect mesangial-cell prolif-
eration in vitro. Th erefore, genes encoding 
enzymes involved in the O-glycosylation 
process of IgA1 hinge peptides are attrac-
tive, reasonable, and functional candidates 
for genetic association study.
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A case-control study by Li et al.6 (this 
issue) shows for the fi rst time an associa-
tion of genetic polymorphisms in the gene 
encoding a key enzyme of O-glycosylation 
of protein, C1GALT1, with susceptibility 
to IgAN. Th is study is the largest popu-
lation-based association study for IgAN 
performed to date. Th e authors selected 
fi ve tagging single-nucleotide polymor-
phisms (SNPs) from nine polymorphisms 
in the entire C1GALT1 gene, using spe-
cialized soft ware, and showed that the 
frequency of the haplotype of YATIG was 
signifi cantly lower, and those of YAGDA 
and YATDG were higher, in the IgAN 
patients than in the control subjects. Th e 
minor allele frequency of the polymor-
phism with the most signifi cant diff er-
ence in this study, SNP7, was relatively 
low (D:I = 0.872:0.128 and 0.909:0.091 
in IgAN patients and in controls, respec-
tively, P = 0.004). Th is supports the recent 
rare variant–common disease hypothesis, 
which posits that several rare variants in 
a gene are involved in the causality of a 
common disease. However, the frequency 
of YATIG, the haplotype bearing the I 
allele — which was signifi cantly more 
abundant in IgAN in the simple associa-
tion analysis using each SNP — was lower 
in IgAN patients than in controls, and 
the frequencies of YAGDA and YATDG, 
bearing the D allele, were higher in IgAN 
patients. No reasonable explanation was 
provided for these data, which appeared 
to contradict each other. Th e authors also 
investigated C1GALT1C1, the gene for 
Cosmc (core 1 β3-Gal-T-specifi c mole-
cular chaperone), because it has recently 
been demonstrated that Cosmc is essen-
tially required for the C1GALT1 activity.7 
However, there was no signifi cant associa-
tion with the C1GALT1C1 gene polymor-
phisms. Although the authors speculate 
that variations in C1GALT1 might infl u-
ence the enzyme activity by altering the 
expression of this gene, further functional 
studies are necessary to validate the role 
of these genetic polymorphisms in the 
development of IgAN. In addition, more 
studies are required to examine the asso-
ciation of this candidate gene with IgAN 
in diff erent ethnic and racial groups. In 
this regard, the recent organization of a 
multicenter Biobank for the collection of 
biological samples and clinical data from 
IgAN patients and relatives by European 
groups may be useful.8
On the other hand, because pp-Gal-
NAc-Ts determine the number and posi-
tion of O-glycans, they are biologically 
important. To date, it has been shown 
that at least six pp-GalNAc-Ts, pp-Gal-
NAc-T1, -T2, -T3, -T4, -T6, and -T9, 
were expressed in IgA-bearing B cells. 
Th e pp-GalNAc-T activities of these six 
enzymes for a synthetic IgA hinge peptide 
were examined by Iwasaki et al.3 Th ey 
reported that pp-GalNAc-T2 had the 
strongest activity of transferring GalNAc, 
and that other pp-GalNAc-Ts exhibited 
substrate specifi cities diff erent from that 
of pp-GalNAc-T2, with weaker activity. It 
was reported that the IgA1 hinge region 
possesses a maximum of fi ve O-glycans, 
and that pp-GalNAc-T2 selectively trans-
ferred GalNAc residues to the same fi ve 
positions, suggesting that pp-GalNAc-T2 
was an essential enzyme for initiation of 
O-linked glycosylation of the IgA1 hinge 
region. Th erefore, pp-GalNAc-T2 may be 
another reasonable candidate for genetic 
association analysis.
Although the study by Li et al.6 is 
based on the premise that the abnor-
mal O-glycosylation is congenitally 
determined by genetic predisposition, 
there is another possibility, that it may 
be acquired epigenetically. Interest-
ingly, among immunoglobulin isotypes, 
only IgD and IgA1 are O-glycosylated. 
Whereas IgA is produced by mature B 
cells, IgD is formed early in B-cell devel-
opment. For investigation of the stage 
of B-cell maturation at which the defect 
seen in IgAN arises, Smith et al.9 studied 
the O-glycans of serum IgA1 and IgD in 
20 patients with IgAN and 20 controls. 
They found that the underglycosyla-
tion was not shared by IgD. Compared 
with that in controls, O-glycosylation in 
IgAN patients was incomplete in IgA1 
but more complete in IgD, suggesting 
that the incompleteness in IgA1 O-gly-
cosylation is not due to an inherent defect 
in glycosylation mechanisms but rather 
arises at a later stage in B-cell develop-
ment and may be secondary to aberrant 
immunoregulation.9 However, precise 
structural analyses of O-glycans of IgD in 
IgAN, such as those using time-of-fl ight 
mass spectrometry, have not yet been 
performed. Because there is no direct evi-
dence indicating that the incompleteness 
of O-glycosylation of IgA1 is the primary 
and fundamental defect in the pathogen-
esis of IgAN, it may be useful to analyze 
sera from patients with IgAN aft er com-
plete remission of glomerulonephritis or 
from their relatives, who may share the 
genetic predisposition to IgAN.
Recent progress in glycobiology has 
facilitated our understanding of the 
molecular mechanisms of glycosylation 
of proteins and provided new targets to 
be investigated in the research into the 
pathogenesis of IgAN. Th e identifi cation 
of the susceptible genes may lead to an 
understanding of the pathogenesis of 
IgAN, if the mechanism accounting for 
linkage or association in the genetic stud-
ies can be functionally proven and sup-
ported by biochemical, physiological, and 
clinical studies. In this respect, there is 
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Figure 1 | Initiation of O-glycan biosynthesis. O-Glycosylation of protein is initiated by the 
addition of GalNAc to serine or threonine residues through the activity of UDP-N-acetyl-α-D-
galactosamine:polypeptide N-acetylgalactosaminyltransferases (pp-GalNAc-Ts), which is followed 
by β-galactosylation through core 1 synthase 1, also called glycoprotein-N-acetylgalactosamine 
3-β-galactosyltransferase 1, core 1 β3-Gal-T, or T-synthase (C1GALT1).
Kidney International (2007) 71       381
commentar y
no single gene that has been confi rmed 
to be responsible for the development of 
IgAN to date. Both family-based genetic 
linkage studies and large-scale association 
studies based on a combined strategy of 
genetic and molecular–cellular biological 
investigations are necessary to clarify the 
pathogenesis of common diseases includ-
ing IgAN.
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